Aims. Carisoprodol is a muscle relaxant that acts at the GABAA receptor. Concerns about the abuse liability of carisoprodol are increasing, but evidence that carisoprodol produces tolerance and a significant withdrawal syndrome has yet to be established. The purpose of the current study was to determine.
Any signs on either scale that were scored 0 on all time points were discarded. Overall, the rating scale is sensitive to carisoprodol withdrawal and appears to have external validity. Other signs reported in humans such as insomnia, heart palpitations and stomach cramps ( Heacock and Bauer, 2004 ; Morse and Chua, 1978 ; Reeves et al., 2004 ; Rohatgi et al., 2005 ) are difficult to measure in mice. Because earlier work indicated that carisoprodol produced effects mainly through the barbiturate site on the the GABA A receptor ( Gonzalez et al., 2009 ), a barbiturate withdrawal scale ( Yutrzenka, 1989 ; Yutrzenka et al., 1996 ) was used as the primary model for the scale used in the present study.
Abstract. Carisoprodol is a commonly used skeletal muscle relaxant with potential for abuse because of its active metabolite, meprobamate, and several reports have suggested that patients abruptly stopping intake of carisoprodol may have a withdrawal syndrome. The authors studied changes in the occurrence of somatic.
This PDF is available to Subscribers Only.
View Article Abstract & Purchase Options Cancel.
Carisoprodol is a commonly used skeletal muscle relaxant with potential for abuse because of its active metabolite, meprobamate, and several reports have suggested that patients abruptly stopping intake of carisoprodol may have a withdrawal syndrome. The authors studied changes in the occurrence of somatic dysfunctions in five patients during an 8-day period following discontinuation from large doses of carisoprodol. Results showed that the number of somatic dysfunctions changed significantly during the withdrawal period. Each patient had an increase in the number of somatic dysfunctions during the first 3 days after cessation of carisoprodol with return to at or near baseline by the eighth day. This was reflected statistically in a significant-within-subjects effect for time. Increases in the number of somatic dysfunctions during carisoprodol discontinuation support the existence of a carisoprodol withdrawal syndrome. Results of supplemental analyses revealed a significant component of the effect and a trend for the quadratic component to be significant.
RR Reeves, JD Parker. Download citation file: 2017. J Am Osteopath Assoc 2003;103(2):75–80. doi: 10.7556/jaoa.2003.103.2.75. Somatic dysfunction during carisoprodol cessation: evidence for a carisoprodol withdrawal syndrome.
Carisoprodol Withdrawal Syndrome. Roy R. Reeves, D.O., Ph.D., John J. Beddingfield, M.D., and James E. Mack, Ph.D. A 43-year-old man with chronic back and shoulder pain was treated with hydrocodone. He began taking excessive amounts of the drug, so his physicians stopped prescribing it. The patient then obtained.
Register now >. Search for your institution's name below to login via Shibboleth.
Login via OpenAthens or.
Request (PDF) | Carisoprodol Withdra | Carisoprodol is a centrally acting muscle relaxant used in the treatment of various musculoskeletal disorders whose main metabolite, meprobamate, is a controlled substance in the United States due to its sedative properties and potential for abuse. We report a case of a 51-year-old.